Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open label, single arm, single centre study to evaluate the safety/tolerability, immunogenicity and preliminary efficacy of AMV002 when co-administered with anti-PD-L1 immunotherapy, Durvalumab (MEDI4736), in patients with recurrent and/or metastatic HPV-related, p16 positive oropharyngeal squamous cell carcinoma (OPSCC)

Next Previous
Trial Profile

Open label, single arm, single centre study to evaluate the safety/tolerability, immunogenicity and preliminary efficacy of AMV002 when co-administered with anti-PD-L1 immunotherapy, Durvalumab (MEDI4736), in patients with recurrent and/or metastatic HPV-related, p16 positive oropharyngeal squamous cell carcinoma (OPSCC)

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMV-002 (Primary) ; Durvalumab (Primary)
  • Indications Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms DURVAX

Most Recent Events

  • 01 Nov 2021 Planned End Date changed from 31 Mar 2022 to 15 Aug 2022.
  • 01 Nov 2021 Status changed from recruiting to active, no longer recruiting.
  • 21 Apr 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top